Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2018 Jul 19;17(10):2112–2122. doi: 10.1158/1535-7163.MCT-17-0131

Figure 4:

Figure 4:

a) Cabozantinib significantly reduced glucose uptake measured by [18F] FDG-PET on day 7 and day 28 of treatment compared to baseline; b) Western Blot analysis revealed a decrease in protein expression of pyruvate dehydrogenase after cabozantinib treatment compared to regorafenib and control.